GW6471

SIGMA/G5045 - ≥98% (HPLC)

Synonym: N-((2S)-2-(((1Z)-1-Methyl-3-oxo-3-(4-(trifluoromethyl)phenyl)prop-1-enyl)amino)-3-(4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)propyl)propanamide

CAS Number: 880635-03-0
Empirical Formula (Hill Notation): C₃₅H₃₆F₃N₃O₄
Molecular Weight: 619.67
MDL Number: MFCD07784503
Linear Formula: C₃₅H₃₆F₃N₃O₄
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-G5045-5MG	5 mg	$310.00 1/EA	Add To Favorites

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98% (HPLC)
color	white to beige
form	powder
InChI	1S/C35H36F3N3O4/c1-4-33(43)39-22-29(40-23(2)20-32(42)26-12-14-28(15-13-26)35(36,37)38)21-25-10-16-30(17-11-25)44-19-18-31-24(3)45-34(41-31)27-8-6-5-7-9-27/h5-17,20,29,40H,4,18-19,21-22H2,1-3H3,(H,39,43)/b23-20-/t29-/m0/s1
InChI key	TYEFSRMOUXWTDN-DYQICHDWSA-N
originator	GlaxoSmithKline
Quality Level	100
SMILES string	CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c3ccccc3)cc1)NC(C)=C/C(=O)c4ccc(cc4)C(F)(F)F
solubility	DMSO: 5 mg/mL, clear (warmed)
storage condition	desiccated
storage temp.	2-8°C

Application:	GW6471 has been used: • to investigate the role of peroxisome proliferator-activated receptors (PPARs) alpha in perfluorooctanoic acid (PFOA) induced developmental cardiotoxicity • to abolish the protection of bezafibrate (BZA) against hypertrophy • to block the enhanced activity of the hepatitis B virus (HBV) core promoter
Biochem/physiol Actions:	GW6471 is a PPARα antagonist, which completely inhibits GW409544-induced activation of PPARα with an IC₅₀ = 0.24 μM. GW6471 induces a PPARα conformation that interacts efficiently with co-repressors.
Features and Benefits:	This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm .
Features and Benefits:	This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here .
Features and Benefits:	This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here .
General description:	GW6471 prevents apoptosis and cell cycle arrest at G₀/G₁ in renal cell carcinoma. It reduces enhanced fatty acid oxidation and oxidative phosphorylation associated with glycolysis inhibition.
Packaging:	5 mg in glass bottle

Hazard Codes	Xi
Risk Statements	36/37/38
Safety Statements	26-36
RIDADR	NONH for all modes of transport
WGK Germany	WGK 3
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥98% (HPLC)
Storage Temp.	2-8°C
UNSPSC	12352200

To Order From a Quote